Trial Profile

Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Antineoplastics
Indications Malignant ascites
Focus Therapeutic Use

Most Recent Events

01 Sep 2015 Assumed phase chosen as II rather than IV as bevacizumab was not approved for peritoneal cancer indication in EU until Aug 2014. Formulation is perfusion, but this is not listed in available formulations for CT.
01 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com